Biotech Players Lead the Growth Charge in the Legal Cannabis Market

The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug RD, but vulnerable to the risk of stringent regulatory approval processes. Within this volatile market, however, is the cannabis-biotech sub-sector – a market flourishing with opportunity, innovation, and deep roots of medical possibilities. Fueled by an increasing volume of supportive research, cannabis-based biotech companies are addressing large markets of unmet medical need while rising to meet global demand of epic proportion. Included among several companies in the cannabis-biotech sub-sector is Lexaria Bioscience Corp. (OTC: LXRP) (CSE: LXX.CN) (LXRP Profile), a company emerging as a recognizable name within a space occupied by companies like GW Pharmaceuticals PLC (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Insys Therapeutics, Inc. (NASDAQ: INSY) and Axim Biotechnologies Inc. (OTC: AXIM).

Because the cannabis-biotech

... read more at: http://www.prnewswire.com/news-releases/biotech-players-lead-the-growth-charge-in-the-legal-cannabis-market-636940223.html

Leave a Reply

Your email address will not be published. Required fields are marked *